Chylothorax: Difference between revisions
| Line 156: | Line 156: | ||
*If left untreated, 100% of patients with chylothorax may progress to develop<ref name="pmid19766473">{{cite journal| author=McGrath EE, Blades Z, Anderson PB| title=Chylothorax: aetiology, diagnosis and therapeutic options. | journal=Respir Med | year= 2010 | volume= 104 | issue= 1 | pages= 1-8 | pmid=19766473 | doi=10.1016/j.rmed.2009.08.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19766473 }} </ref><ref name="pmid25829744">{{cite journal| author=Das J, Thambudorai R, Ray S| title=Lymphoscintigraphy combined with single-photon emission computed tomography-computed tomography (SPECT-CT): A very effective imaging approach for identification of the site of leak in postoperative chylothorax. | journal=Indian J Nucl Med | year= 2015 | volume= 30 | issue= 2 | pages= 177-9 | pmid=25829744 | doi=10.4103/0972-3919.152988 | pmc=4379685 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25829744 }} </ref> | *If left untreated, 100% of patients with chylothorax may progress to develop<ref name="pmid19766473">{{cite journal| author=McGrath EE, Blades Z, Anderson PB| title=Chylothorax: aetiology, diagnosis and therapeutic options. | journal=Respir Med | year= 2010 | volume= 104 | issue= 1 | pages= 1-8 | pmid=19766473 | doi=10.1016/j.rmed.2009.08.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19766473 }} </ref><ref name="pmid25829744">{{cite journal| author=Das J, Thambudorai R, Ray S| title=Lymphoscintigraphy combined with single-photon emission computed tomography-computed tomography (SPECT-CT): A very effective imaging approach for identification of the site of leak in postoperative chylothorax. | journal=Indian J Nucl Med | year= 2015 | volume= 30 | issue= 2 | pages= 177-9 | pmid=25829744 | doi=10.4103/0972-3919.152988 | pmc=4379685 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25829744 }} </ref> | ||
**[[Hypovolaemia]] | **[[Hypovolaemia]] | ||
*[[Hypoalbuminemia]] | **[[Hypoalbuminemia]] | ||
**[[Malnutrition]]; as a result of [[protein]], [[fats]] and [[vitamin]]s loss with [[weight loss]] and [[Muscle atrophy|muscle wasting]]. | **[[Malnutrition]]; as a result of [[protein]], [[fats]] and [[vitamin]]s loss with [[weight loss]] and [[Muscle atrophy|muscle wasting]]. | ||
**[[Hyponatremia]] and [[hypocalcemia]] due to [[Electrolyte disturbance|electrolyte loss]]. | **[[Hyponatremia]] and [[hypocalcemia]] due to [[Electrolyte disturbance|electrolyte loss]]. | ||
Revision as of 19:37, 30 July 2020
| Chylothorax | |
| ICD-10 | I89.8, J91 |
|---|---|
| ICD-9 | 457.8, 511.9 |
| DiseasesDB | 29612 |
| eMedicine | med/381 |
| MeSH | D002916 |
|
WikiDoc Resources for Chylothorax |
|
Articles |
|---|
|
Most recent articles on Chylothorax Most cited articles on Chylothorax |
|
Media |
|
Powerpoint slides on Chylothorax |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Chylothorax at Clinical Trials.gov Clinical Trials on Chylothorax at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Chylothorax
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Chylothorax Discussion groups on Chylothorax Patient Handouts on Chylothorax Directions to Hospitals Treating Chylothorax Risk calculators and risk factors for Chylothorax
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Chylothorax |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Chylothorax, a type of pleural effusion is the accumulation of chyle in the pleural cavity secondary to destruction or obstruction of the thoracic duct or its tributaries. It is an uncommon but established complication of thoracic surgery. Chylothorax is most commonly right-sided (50%) because of the anatomic location of the thoracic duct, left-sided (33.3%), or bilateral (16.66%). Thoracic duct damage above the fifth thoracic vertebra results in a left-sided chylothorax whereas damage to the thoracic duct below fifth thoracic vertebra leads to a right-sided effusion. Some common symptoms of chylothorax include dyspnea, cough, and severe chest pain. Some physical exams finding include decreased breath sounds and dullness to percussion depending on the size and location of fluid. The definitive diagnosis of chylothorax is with thoracentesis and analysis of the pleural fluid showing a reduced concentration of cholesterol <200mg/dl, and an elevated concentration of triglyceride >110 mg/dl. Management of chylothorax may be conservative or surgical. Conservative management include total parenteral nutrition, oral low-fat medium-chain triglyceride, and octreotide injections. Surgical management include tube thoracostomy, pleurodesis, pleurectomy, pleuroperitoneal shunt, and thoracic duct ligation.
Historical Perspective
- Chylothorax was first described in 1633 by Bartolet, and Quincke reported the first case in 1875. [1]
- In 1917, Brandt was the first to discover the association between tuberculosis and the development of chylothorax. [1]
Classification
Chylothorax may be classified as[2][3]
- Non-traumatic
- Malignacy
- Idopathic
- Disease
- Sarcoidosis
- Haemangiomatosis
- Tuberculosis
- Heart failure
- Benign tumor
- Amyloidosis
- Lymphangioleiomyomatosis
- Filariasis
- Transdiaphrgmatic movement of chylous ascitic fluid
- SVC obstruction
- Traumatic
- Iatrogenic
- Non-iatrogenic
- Knife injury
- Childbirth
- Forceful cough or emesis
- Blunt trauma to the thorax
- Bullet wound
| Chylothorax | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-traumatic | Traumatic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Malignancy | Diseases | Idopathic | Non- Iatrogenic | Iatrogenic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| - Sarcoidosis
- Haemangiomatosis - Tuberculosis - Heart failure -Benign tumor - Amyloidosis -Lymphangiolei -omyomatosis - Filariasis - Transdiaphrgmatic movement of chylous ascitic fluid - SVC obstruction | - Knife injury
- Childbirth - Forceful cough or emesis - Blunt trauma to the thorax - Bullet wound | - Radiation
- Thoracic surgery - Head and neck surgery | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology
It is thought that chylothorax is the result of leakage of chyle from the thoracic duct or its tributaries. Leakage may be sure to trauma (most common cause), disruption or obstruction.
- Chylothorax as a result of tuberculosis is thought to be produced by the enlargement of the lumbar and the iliac lymph nodes producing obstruction of the cisterna chyli and thoracic duct. This leads to dilatation of the lumbar channels, followed by the opening of collateral anastomosis. With the many lymphaticovenous anastomosis existing between the thoracic duct, and the azygos, intercostal, and Lumbar veins. The increased pressure in the system results in the transudation of chyle into the pleural cavity.[1]
Causes
- Common causes of chylothorax include[1][2][3][4][5]
- Congenital
- Malignacy
- Sarcoidosis
- Tuberculosis
- Heart failure
- Benign tumor
- SVC obstruction
- Thoracic surgery
- Knife injury
- Bullet wound
- Blunt trauma to the thorax
- Head and neck surgery
- Transdiaphrgmatic movement of chylous ascitic fluid
Differentiating chylothorax from other Diseasess
Chylothorax must be differentiated from[3] [6] [7]
- Empyema
- Pseudochylothorax
- Tuberculosis
- Chronic pneumothorax
- Rheumatoid pleurisy
- Chronic hemothorax
- Cirrhosis
- Nephrotic syndrome
- Lymphoma
- Congestive heart failure
- Constrictive pericarditis
Epidemiology and Demographics
- The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
- In 2011, the incidence of pediatric chylothorax was estimated to be 3.7%[8] [9]
- Incidence post cardiothoracic surgeries are between 0.9% and 6.6%.
- Incidence post congenital cardiac anomalies repair is 2.8%4.
- Incidence post esophageal surgeries range from 0.2% to 10%.
Age
Gender
- Chylothorax affects men and women equally.
Race
- There is no racial predilection for chylothorax.
Risk Factors
Common risk factors in the development of Chylothorax] are[2][3][10][11][8][12][13][14][15][4]
- Hepatectomy
- Esophagectomy
- Lung surgery
- Cardiac surgery
- Fontan procedure
- Retroperitoneal surgery around the cisterna chyli, example AAA repair
- Dasatinib therapy
- Rib fracture
- Tuberculosis
- Malignant pleural mesothelioma
- Malignant lymphoproliferative disorders
Screening
- There is insufficient evidence to recommend routine screening for chylothorax.
Natural History, Complications and Prognosis
- If left untreated, 100% of patients with chylothorax may progress to develop[3][16]
- Hypovolaemia
- Hypoalbuminemia
- Malnutrition; as a result of protein, fats and vitamins loss with weight loss and muscle wasting.
- Hyponatremia and hypocalcemia due to electrolyte loss.
- Opportunistic infections as a result of immunoglobulins loss.
- Subtherapeutic effects of medications like digoxin and amiodarone as they are lost through the leaking chyle.
- Common complications of chylothorax include malnutrition, immunosuppression and respiratory distress.[3]
- Prognosis is generally good and the mortality rate from chylothorax has considerably improved from approximately 50% as described in 1948. This is due to the more aggressive management plans implemented. Currently, the worst prognosis is seen in malignant and bilateral chylothoraces.[3][12]
Diagnosis
Diagnostic Study of Choice
- The diagnosis of chylothorax is with thoracentesis and analysis of the pleural fluid showing a reduced concentration of cholesterol <200mg/dl, and an elevated concentration of triglyceride >110 mg/dl. In centres with available facilities, lipoprotein analysis showing the presence of chylomicrons is the gold standard.[2][3][14][1]
History and Symptoms
- Symptoms of chylothorax depresend on the rate of chyle accumulation and etiology. Symptoms may include the following[2][3][4]
- Dyspnea
- Cough
- Pleuritic chest pain
- Fever
- Swelling in the supraclavicular fossa
- Weight loss
- Muscle wasting
- Immunodeficiency
- Malnutrition
Physical Examination
- Patients with chylothorax usually appear to be in respiratory distress
- Physical examination may be remarkable for[14][9]
- Decreased breath sounds on the affected side
- Apneic episodes
- Tachycardia
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- An elevated concentration of pleural fluid triglyceride >110 mg/dL is diagnostic of chylothorax.[2][3][14]
- A reduced concentration of cholesterol <200mg/dl is diagnostic of chylothorax.[3]
- Leukocyte cell count ˃1000, with > 90% lymphocytic predominance.[9]
- Hypoalbuminemia[1]
Electrocardiogram
- There are no ECG findings associated with chylothorax.
X-ray
- An x-ray may be helpful in the diagnosis of chylothorax. Findings on an x-ray suggestive of/diagnostic of chylothorax include.[14][4][9]
- Pleural effusion
- Pleural thickening
- Blunting of the Costophrenic angle
Ultrasound
Transthoracic ultrasound may be helpful in the diagnosis of chylothorax, loculated fluid collection can be seen on an ultrasound. [9]
CT scan
Thoracic CT scan may be helpful in the diagnosis of chylothorax. Findings on CT scan suggestive of/diagnostic of chylothorax include[2]
MRI
Other Imaging Findings
Other diagnostic studies for chylothorax include
- Lymphangiography with Lipiodol (ethiodized oil) [2] which demonstrates the site of extravasation into the pleural cavity.
- lymphoscintigraphy; identify chyle leakage but not the exact site.[12][16][17]
Other Diagnostic Studies
- There are no other diagnostic studies associated with chylothorax.
Treatment
Medical Therapy
Chylothorax is a medical emergency and requires prompt treatment. Medical therapy for chylothorax include[2][3][8] Conservative therapy aims at minimizing lymph flow through the damaged thoracic duct.[16][9][5]
- Total parenteral nutrition
- Oral low-fat medium-chain triglyceride
- Octreotide injections
- Treatment of the underlying condition
- Sarcoidosis with steroids
- Tuberculosis with RIPE
- Congestive heart failure with diuretics
- Intravenous etilefrine
Surgery
Surgery is the mainstay of therapy for chylothorax. Surgery is recommended where despite conservative management, patient drains more than 1.5 l/day in an adult or >100 ml/kg body weight per day in a child, leaks chyle at >1 l/day× 5 days or has persistent chyle flow for >2 weeks. It is also recommended if there is a rapid decline in nutritional status despite conservative management.[2] [3][10][8][16][13][5]
- Thoracentesis
- Tube thoracostomy
- Thoracoscopy
- Pleurodesis with
- Pleurectomy
- pleuroperitoneal shunt
- Thoracic duct ligation
- Lymphatic embolization
Primary Prevention
- There are no established measures for the primary prevention of chylothorax.
Secondary Prevention
- There are no established measures for the secondary prevention of chylothorax.
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Kant S, Verma SK, Anand SC, Prasad R, Verma RK (2011). "Development of bilateral chylothorax in a younger female secondary to tuberculosis". Lung India. 28 (1): 56–9. doi:10.4103/0970-2113.76303. PMC 3099513. PMID 21654988.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Yamamoto R, Mokuno Y, Matsubara H, Kaneko H, Sato Y, Iyomasa S (2018). "Chylothorax after hepatectomy: a case report". J Med Case Rep. 12 (1): 347. doi:10.1186/s13256-018-1882-x. PMC 6260677. PMID 30474568.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 McGrath EE, Blades Z, Anderson PB (2010). "Chylothorax: aetiology, diagnosis and therapeutic options". Respir Med. 104 (1): 1–8. doi:10.1016/j.rmed.2009.08.010. PMID 19766473.
- ↑ 4.0 4.1 4.2 4.3 Rajagopala S, Kancherla R, Ramanathan RP (2018). "Tuberculosis-Associated Chylothorax: Case Report and Systematic Review of the Literature". Respiration. 95 (4): 260–268. doi:10.1159/000484694. PMID 29316546.
- ↑ 5.0 5.1 5.2 Waterfield T, Lakhoo K (2010). "Challenges in the management of refractory bilateral idiopathic congenital chylothoraces in a newborn". Eur J Pediatr Surg. 20 (3): 198–201. doi:10.1055/s-0029-1241874. PMID 19882503.
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
- ↑ 8.0 8.1 8.2 8.3 8.4 Savla JJ, Itkin M, Rossano JW, Dori Y (2017). "Post-Operative Chylothorax in Patients With Congenital Heart Disease". J Am Coll Cardiol. 69 (19): 2410–2422. doi:10.1016/j.jacc.2017.03.021. PMID 28494978.
- ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Muniz G, Hidalgo-Campos J, Valdivia-Tapia MDC, Shaikh N, Carreazo NY (2018). "Successful Management of Chylothorax With Etilefrine: Case Report in 2 Pediatric Patients". Pediatrics. 141 (5). doi:10.1542/peds.2016-3309. PMID 29703801.
- ↑ 10.0 10.1 Lo Rito M, Al-Radi OO, Saedi A, Kotani Y, Ben Sivarajan V, Russell JL; et al. (2018). "Chylothorax and pleural effusion in contemporary extracardiac fenestrated fontan completion". J Thorac Cardiovasc Surg. 155 (5): 2069–2077. doi:10.1016/j.jtcvs.2017.11.046. PMID 29249497.
- ↑ Sasaki H, Kimizuka Y, Ogata H, Okada Y, Ota S, Sano T; et al. (2019). "Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan"". Intern Med. 58 (21): 3139–3141. doi:10.2169/internalmedicine.3002-19. PMC 6875454 Check
|pmc=value (help). PMID 31292394. - ↑ 12.0 12.1 12.2 Nicastri DG, Flores RM (2018). "Chylothorax: Abdominal approach". J Thorac Cardiovasc Surg. 155 (2): 814. doi:10.1016/j.jtcvs.2017.09.111. PMID 29106894.
- ↑ 13.0 13.1 Townshend AP, Speake W, Brooks A (2007). "Chylothorax". Emerg Med J. 24 (2): e11. doi:10.1136/emj.2006.042028. PMC 2658219. PMID 17251600.
- ↑ 14.0 14.1 14.2 14.3 14.4 Benninger LA, Ross JA, Leon ME, Reddy R (2018). "An unusual case of chylothorax". Respir Med Case Rep. 25: 318–322. doi:10.1016/j.rmcr.2018.10.020. PMC 6205929. PMID 30402386.
- ↑ Pospiskova J, Smolej L, Belada D, Simkovic M, Motyckova M, Sykorova A; et al. (2019). "Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders". Orphanet J Rare Dis. 14 (1): 9. doi:10.1186/s13023-018-0991-3. PMC 6327395. PMID 30626415.
- ↑ 16.0 16.1 16.2 16.3 Das J, Thambudorai R, Ray S (2015). "Lymphoscintigraphy combined with single-photon emission computed tomography-computed tomography (SPECT-CT): A very effective imaging approach for identification of the site of leak in postoperative chylothorax". Indian J Nucl Med. 30 (2): 177–9. doi:10.4103/0972-3919.152988. PMC 4379685. PMID 25829744.
- ↑ Turpin S, Lambert R (2018). "Lymphoscintigraphy of Chylous Anomalies: Chylothorax, Chyloperitoneum, Chyluria, and Lymphangiomatosis-15-Year Experience in a Pediatric Setting and Review of the Literature". J Nucl Med Technol. 46 (2): 123–128. doi:10.2967/jnmt.117.203281. PMID 29438003.